These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16028175)

  • 21. Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'.
    Pedrol E; Deig E
    AIDS; 2007 Nov; 21(18):2566. PubMed ID: 18025906
    [No Abstract]   [Full Text] [Related]  

  • 22. Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
    Manfredi R
    Clin Infect Dis; 2006 May; 42(9):1345-7; author reply 1347-8. PubMed ID: 16586399
    [No Abstract]   [Full Text] [Related]  

  • 23. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
    Kakuda TN; Anderson PL; Becker SL
    AIDS; 2004 Dec; 18(18):2442-4. PubMed ID: 15622326
    [No Abstract]   [Full Text] [Related]  

  • 24. Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
    Ripamonti D; Maggiolo F; Suter F
    AIDS; 2007 May; 21(8):1059-60. PubMed ID: 17457107
    [No Abstract]   [Full Text] [Related]  

  • 25. Tenofovir and renal toxicity.
    AIDS Patient Care STDS; 2004 Oct; 18(10):615-6. PubMed ID: 15633256
    [No Abstract]   [Full Text] [Related]  

  • 26. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
    Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum creatinine changes in HIV-seropositive patients receiving tenofovir.
    El Sahly HM; Teeter L; Zerai T; Andrade RA; Munoz C; Nnabuife C; Hunter R
    AIDS; 2006 Mar; 20(5):786-7. PubMed ID: 16514316
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypokalemia in HIV patients on tenofovir.
    Cirino CM; Kan VL
    AIDS; 2006 Aug; 20(12):1671-3. PubMed ID: 16868451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
    Soler-Palacín P; Melendo S; Noguera-Julian A; Fortuny C; Navarro ML; Mellado MJ; Garcia L; Uriona S; Martín-Nalda A; Figueras C
    AIDS; 2011 Jan; 25(2):171-6. PubMed ID: 21076275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to Blaas et al., 'Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases'.
    Ranneberg B; Mertenskoetter T; Pearce G
    AIDS; 2007 Mar; 21(6):783. PubMed ID: 17413708
    [No Abstract]   [Full Text] [Related]  

  • 31. HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
    AIDS Patient Care STDS; 2009 Aug; 23(8):680-1. PubMed ID: 19694040
    [No Abstract]   [Full Text] [Related]  

  • 32. Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
    Winston J; Shepp DH
    HIV Med; 2006 Oct; 7(7):484-5. PubMed ID: 16925736
    [No Abstract]   [Full Text] [Related]  

  • 33. Acute renal failure after initiation of tenofovir disoproxil fumarate.
    Hynes P; Urbina A; McMeeking A; Barisoni L; Rabenou R
    Ren Fail; 2007; 29(8):1063-6. PubMed ID: 18067059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low incidence of renal impairment observed in tenofovir-treated patients.
    O'Donnell EP; Scarsi KK; Darin KM; Gerzenshtein L; Postelnick MJ; Palella FJ
    J Antimicrob Chemother; 2011 May; 66(5):1120-6. PubMed ID: 21393145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Editorial comment: tenofovir nephrotoxicity--vigilance required.
    Fine DM
    AIDS Read; 2005 Jul; 15(7):362-3. PubMed ID: 16044578
    [No Abstract]   [Full Text] [Related]  

  • 36. Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
    Brim NM; Cu-Uvin S; Hu SL; O'Bell JW
    AIDS Read; 2007 Jun; 17(6):322-8, C3. PubMed ID: 17632940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.
    Lanzafame M; Lattuada E; Rapagna F; Gottardi M; Vento S
    Clin Infect Dis; 2006 Jun; 42(11):1656-7; author reply 1658. PubMed ID: 16652329
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature.
    Malik A; Abraham P; Malik N
    J Infect; 2005 Aug; 51(2):E61-5. PubMed ID: 16038754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
    James JS
    AIDS Treat News; 2001 Aug; (370):3-4. PubMed ID: 11570163
    [No Abstract]   [Full Text] [Related]  

  • 40. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
    Ter Heine R; Huitema AD; Jansen RS; Smits PH; van Gorp EC; Wagenaar JF; Beijnen JH; Mulder JW
    Antivir Ther; 2009; 14(2):299-301. PubMed ID: 19430105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.